Carmen Stelea
Internal Medicine · Springfield, MANPI 1841440393
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $449 and has fallen 95.0% since, to $23 in 2024.
Across 52 payments — averaging $18.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$142
- Johnson & Johnson$90
- AstraZeneca$71
- Amarin Pharma, Inc.$68
- Lilly USA, LLC$60
- Boehringer Ingelheim$55
- plus $484 from 17 others
What the payments were for
- Food & beverage$95598%
- Other$152%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 6 | $142 |
| Johnson & Johnson | 5 | $90 |
| AstraZeneca | 5 | $71 |
| Amarin Pharma, Inc. | 3 | $68 |
| Lilly USA, LLC | 4 | $60 |
| Boehringer Ingelheim | 3 | $55 |
| Amgen | 2 | $51 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Pfizer | 3 | $43 |
| Scilex Pharmaceuticals Inc. | 2 | $41 |
| Exeltis, USA Inc. | 2 | $41 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Almatica Pharma LLC | 1 | $29 |
| Novartis | 1 | $25 |
| Medtronic | 1 | $24 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| Genentech USA, Inc. | 1 | $19 |
| Therapeuticsmd, Inc. | 1 | $19 |
| Myovant Sciences Inc. | 1 | $17 |
| Welch Allyn | 1 | $15 |
| Mylan Pharmaceuticals Inc. | 1 | $15 |
| Merck | 1 | $12 |
How this compares
$970 in reported general payments places this provider in the 80th percentile of 4,983 internal medicine providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 12 | $8,027 |
| Olmesartan Medoxomil | 12 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $142 | $8,02712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Springfield
- David SchenkeinBoston$5M
- Alan GarberCambridge$4.9M
- John FallonBoston$1.8M
- Michael MendelsohnBoston$1.6M
- Sandra RichmanBrookline$1.4M
- Gaurav SingalBoston$798K
- Asit ParikhBoston$486K
- Noopur RajeBoston$481K
- Daniel KuritzkesBoston$443K
- Xiuning leBoston$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.